The researchers reviewed medical records from 180 adult patients who underwent single-level PLDFs and calculated costs for allogeneic blood transfusion, setting up the cell saver recovery system and infusing autologous blood from cell saver. Averted blood transfusions and quality-adjusted life years marked effectiveness.
Transfusion rate decreased from 40 to 38.7 percent with the cell saver approach, with a cost effectiveness ratio of $55,538 per allogeneic transfusion averted. The cell saver approach was not cost effective with a ratio of $5.6 million per quality-adjusted life years, above the cost-effective threshold of $100,000 per life year.
More Articles on Spine:
Dr. Hussein Alahmadi Joins The Hospital of Central Connecticut
5 Factors for Spine Surgeons to Negotiate Better Payor Contracts
7 Trends Impacting the Future of Spinal Surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.